<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073008</url>
  </required_header>
  <id_info>
    <org_study_id>EGF20014</org_study_id>
    <nct_id>NCT00073008</nct_id>
    <nct_alias>NCT00084955</nct_alias>
  </id_info>
  <brief_title>A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate and compare the efficacy of two dose schedules of an oral
      investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,
    further enrollment was stopped due to lack of efficacy
  </why_stopped>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response in the Targeted Population Through the End of Treatment</measure>
    <time_frame>Baseline and then every 8 weeks through end of treatment</time_frame>
    <description>Disease progression and tumor response (number of participants achieving a complete response [CR] or partial response [PR]), using standardized criteria (Response evaluation criteria in solid tumors). CR, disappearance of all target lesions; PR, 30% decrease in the sum of the longest diameter of target lesions; progressive disease, 20% increase in the sum of the longest diameter of target lesions; stable disease, small changes that do not meet above criteria. Disease assessment was done at baseline and then every 8 weeks after starting treatment, until the participant discontinued treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) at Four Months in the Targeted Population</measure>
    <time_frame>From randomization and then every 8 weeks up to four months</time_frame>
    <description>Percentage of participants in the Targeted Population, at 4 months after starting study drug, who were alive and without disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) at Four Months in the Non-Targeted Population</measure>
    <time_frame>From randomization and then every 8 weeks up to four months</time_frame>
    <description>Percentage of participants in the Non-Targeted Population, at 4 months after starting study drug, who were alive and without disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Showed Certain Biomarkers in Their Serum or Tumor Tissue</measure>
    <time_frame>From randomization to disease progression (for serum biomarkers) or until analyses of tumor tissue samples</time_frame>
    <description>To further characterize the participant population, these biomarkers could be tested: serum levels of ErbB1 and ErbB2; intra-tumoral expression of ErbB1, ErbB2, etc.; mutations in ErbB1, ErbB2, and k-ras. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, serum biomarkers were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Lapatinib</measure>
    <time_frame>From randomization to time of PK period completed: Day 1 (first dose) and Days 2, 28, and 29 while participant was on study drug</time_frame>
    <description>To characterize the PK (absorption, distribution, metabolism, and excretion) of the study drug lapatinib in the participant population. PK is defined as the concentration of drug in a participant's blood at certain time points after the drug was taken by mouth. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, pharmacokinetics were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics (PgX)</measure>
    <time_frame>From randomization at every 4-week assessment through end of treatment</time_frame>
    <description>To (1) investigate the relationship between genetic variants in specific genes and the absorption, distribution, metabolism, and excretion (pharmacokinetics) of lapatinib, and to (2) investigate the relationship between genetic variants in select genes in DNA and the response (safety, efficacy, and tolerability) to lapatinib. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, pharmacogenetics were not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline and then every 4 weeks through end of treatment</time_frame>
    <description>Standard survey forms were completed by the participant at scheduled assessments to find out how the participant felt while on study. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, quality of life was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>From randomization and then every 8 weeks to time of response to study drug</time_frame>
    <description>Time from randomization until first documented evidence of partial or complete tumor response, measured using standard criteria (RECIST). Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, time to response was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Time from first documented evidence of response to study treatment and then every 8 weeks until disease progression or death</time_frame>
    <description>For those participants who show a complete or partial response, duration of response would be time from first documented evidence of response (complete or partial response by RECIST) until disease progression or death, if sooner. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, duration of response was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>From randomization and then every 8 weeks to disease progression or death</time_frame>
    <description>Time from randomization until the first documented sign of disease progression or death due to any cause, if sooner. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, time to tumor progression was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization and then every 8 weeks while on study drug and then every 3 months as follow-up until death</time_frame>
    <description>Overall survival is measured as the time from randomization until death due to any cause. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, overall survival was not analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Review of Non-small Cell Lung Cancer (NSCLC) Histology (Cell Type) Using an Independent Review</measure>
    <time_frame>Anytime from Baseline through end of study</time_frame>
    <description>Comparison of the specific cell type (histology) of non-small cell lung cancer from participant's tissue samples, as determined by local pathologist, to the type determined by an independent pathologist. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, NSCLC histology was not analyzed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor Response in the Non-Targeted Population Through the End of Treatment</measure>
    <time_frame>Baseline and then every 8 weeks through end of treatment</time_frame>
    <description>Baseline and then every 8 weeks through end of treatment (end of treatment for each participant was dependent on when the participant withdrew from study therapy due to disease progression, an adverse event or participant decision)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Lung Cancer, Non-Small Cell</condition>
  <arm_group>
    <arm_group_label>lapatinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW572016 (lapatinib)</intervention_name>
    <description>tyrosine kinase inhibitor</description>
    <arm_group_label>lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent;

          -  Subjects must have histologically confirmed advanced (incurable stage IIIB or IV
             according to the International Staging System, [Mountain, 1997] Non-Small Cell Lung
             Cancer (NSCLC) at primary diagnosis or relapsed after curative-intent surgery. Only
             patients with either (1) the histological subtypes of adenocarcinoma with BAC
             (Bronchioloalveolar) features or pure BAC (as defined by the 1999 World Health
             Organization criteria) or, (2) never smokers (i.e. smoked &lt;100 cigarettes in lifetime)
             with any histology of NSCLC (squamous, adenocarcinoma, lifetime) with any histology of
             NSCLC (squamous, adenocarcinoma,

          -  Patients can have had a maximum of 1 prior systemic therapy (chemotherapy or biologic
             therapy) for NSCLC that ended at least 3 weeks prior to enrollment. Patients that have
             had adjuvant cytotoxic chemotherapy that ended at least 3 months prior to enrollment
             are eligible. Prior surgery and radiotherapy are permitted. Patients should recover
             from acute side effects of radiation before enrollment (3-4 weeks). Concurrent
             radiotherapy is prohibited;

          -  Archived tumor tissue available for evaluation of genetic and intra-tumoral protein or
             mRNA expression levels of relevant biomarkers. A minimum of 10 slides of archived
             tumor tissue is required; however, 15 slides should be sent, if available. For
             patients diagnosed on the basis of pleural effusions, efforts should be made to
             provide as many slides as possible made with cells obtained from pleural aspirates.
             Results of biomarkers will not be used to determine subject eligibility for the study;

          -  Measurable lesion(s) according to RECIST (e.g., ≥15 mm with conventional techniques
             (medical photograph [skin or oral lesion], palpation, plain X-ray, CT, MRI, or ≥10 mm
             with spiral CT scan);

          -  At least 1 measurable lesion located outside of the prior radiation field or, if
             located within the prior field of irradiation, is increasing in size;

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1;

          -  Life expectancy of ≥ 12 weeks;

          -  ≥ 18 years old;

          -  A female is eligible to enter and participate in this study if she is of: •
             Non-childbearing potential (i.e., women with functioning ovaries who have a current
             documented tubal ligation, women who had a hysterectomy, women who are
             post-menopausal, or women who have had both ovaries surgically removed); or •
             Childbearing potential (i.e., women with functioning ovaries and no documented
             impairment of oviductal or uterine function that would cause sterility). This category
             includes women with oligomenorrhea (even severe), women who are perimenopausal, and
             young women who have begun to menstruate. Women of childbearing potential must have a
             negative serum pregnancy test at screening, and agree to 1 of the following: a
             Complete abstinence from intercourse from 2 weeks prior to administration of the first
             dose of GW572016 until 28 days after the final dose of GW572016; or b Consistent and
             correct use of 1 of the following acceptable methods of birth control: 1. Male partner
             who is sterile prior to the female subject's entry into the study and is the sole
             sexual partner for that female subject; or 2. Implants of levonorgestrel 3. Injectable
             progestogen 4. Any intrauterine device (IUD) with a documented failure rate of less
             than 1% per year; or 5. Oral contraceptives (either combined or Progestogen only) 6.
             Barrier methods including diaphragm or condom with a spermicide

          -  Able to swallow and retain oral medication;

          -  Cardiac ejection fraction within the institutional range of normal as measured by
             echocardiogram. Subjects with known history of uncontrolled or symptomatic
             echocardiogram. Subjects with known history of uncontrolled or symptomatic angina,
             arrhythmias, or congestive heart failure are not eligible;

          -  Have adequate organ function as defined in Table 1 Baseline Laboratory Values for
             Inclusion;

          -  Subjects must complete all screening assessments as outlined in the protocol.

        Exclusion Criteria:

          -  Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel. Subjects with ulcerative colitis are also
             excluded;

          -  History of other malignancy. Subjects who have been disease-free for 5 years, or
             subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible;

          -  Concurrent disease or condition that would make the subject inappropriate for study
             participation, or any serious medical disorder that would interfere with the subject's
             safety;

          -  Unresolved or unstable, serious toxicity from prior administration of another
             investigational drug;

          -  Active or uncontrolled infection;

          -  Dementia, altered mental status, or any psychiatric condition that would prohibit the
             understanding or rendering of informed consent;

          -  Uncontrolled angina, arrhythmias, or congestive heart failure. Patients whose symptoms
             are under control are eligible.

          -  Known history of or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis except for individuals who have previously treated CNS
             metastases, are asymptomatic, and have had no requirement for steroids or antiseizure
             medication for ≥ 3 months prior to study enrollment. Routine screening with CNS
             imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is
             required only if clinically indicated or if the subject has a history of CNS
             metastases;

          -  Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,
             biologic therapy, hormonal therapy, and tumor embolization).

          -  Concurrent treatment with an investigational agent or participation in another
             clinical trial

          -  Use of an investigational drug within 30 days or 5 half-lives, whichever is longer,
             preceding the first dose of GW572016;

          -  Prior therapy with any ErbB1 and/or ErbB2 inhibitor;

          -  The subject has a known immediate or delayed hypersensitivity reaction or idiosyncrasy
             to drugs chemically related to GW572016.

          -  Has taken/received the following inhibitors of CYP3A4 within the specified number of
             days prior to the first dose of study medication: Seven (7) days: antibiotics
             (clarithromycin, erythromycin, troleandomycin), antiretrovirals (delavirdine),
             protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir, amprenavir,
             lopinavir), systemic antifungals (itraconazole, ketoconazole, voriconazole,
             fluconazole (doses of 200 mg/day and above)), antidepressants (nefazodone,
             fluovoxamine), calcium channel blockers (verapamil, diltiazem), gastrointestinal
             (cimetidine, aprepitant), and grapefruit or its juice. Six (6) months: amiodarone.

          -  Has taken/received the following inducers of CYP3A4 within fourteen (14) days prior to
             the first dose of study medication: glucocorticoids (dexamethasone or dexamethasone
             equivalent dose &gt; 1.5mg/day (see chart in Section 7.2 for conversion), anticonvulsants
             (phenytoin, carbamazepine, phenobarbital), efavirenz, nevirapine, antibiotics
             (rifampin (rifampicin), rifabutin, rifapentine), St. John's Wort and modafinil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904-2007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Colin F Spraggs, Laura R Parham, Christine M. Hunt and Colin T Dollery. Characterisation of lapatinib-associated DILI cases by Class II HLA and UGT1A1*28 genotypes. [Clin Pharmacol Ther]. 2012;</citation>
  </reference>
  <reference>
    <citation>Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010 Mar 15;16(6):1938-49. doi: 10.1158/1078-0432.CCR-08-3328. Epub 2010 Mar 9.</citation>
    <PMID>20215545</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2003</study_first_submitted>
  <study_first_submitted_qc>November 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2003</study_first_posted>
  <results_first_submitted>June 15, 2009</results_first_submitted>
  <results_first_submitted_qc>November 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2010</results_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>ErbB1</keyword>
  <keyword>ErbB2</keyword>
  <keyword>metastatic</keyword>
  <keyword>lapatinib</keyword>
  <keyword>Her-2/neu</keyword>
  <keyword>protein kinase inhibitor</keyword>
  <keyword>BAC</keyword>
  <keyword>GW572016</keyword>
  <keyword>Advanced</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lapatinib 1500 mg QD</title>
          <description>Oral lapatinib 1500 mg once daily (QD)</description>
        </group>
        <group group_id="P2">
          <title>Lapatinib 500 mg BID</title>
          <description>Oral lapatinib 500 mg twice daily (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>&quot;Other&quot; selected on Case Report Form</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lapatinib 1500 mg QD</title>
          <description>Oral lapatinib 1500 mg once daily (QD)</description>
        </group>
        <group group_id="B2">
          <title>Lapatinib 500 mg BID</title>
          <description>Oral lapatinib 500 mg twice daily (BID)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="12.03"/>
                    <measurement group_id="B2" value="65.2" spread="10.56"/>
                    <measurement group_id="B3" value="65.1" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology at diagnosis</title>
          <description>Type of lung cancer</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Squamous cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchioloalveolar carcinoma (BAC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenocarcinoma with BAC features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenocarcinoma without BAC features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other non-small cell lung cancer type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response in the Targeted Population Through the End of Treatment</title>
        <description>Disease progression and tumor response (number of participants achieving a complete response [CR] or partial response [PR]), using standardized criteria (Response evaluation criteria in solid tumors). CR, disappearance of all target lesions; PR, 30% decrease in the sum of the longest diameter of target lesions; progressive disease, 20% increase in the sum of the longest diameter of target lesions; stable disease, small changes that do not meet above criteria. Disease assessment was done at baseline and then every 8 weeks after starting treatment, until the participant discontinued treatment.</description>
        <time_frame>Baseline and then every 8 weeks through end of treatment</time_frame>
        <population>Targeted Population: all randomized participants who received at least one dose of study drug and had either the histological subtypes of adenocarcinoma with bronchioloalveolar carcinoma features or pure bronchioloalveolar carcinoma, or were never smokers with any histology of non-small cell lung cancer (NSCLC)</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response in the Targeted Population Through the End of Treatment</title>
          <description>Disease progression and tumor response (number of participants achieving a complete response [CR] or partial response [PR]), using standardized criteria (Response evaluation criteria in solid tumors). CR, disappearance of all target lesions; PR, 30% decrease in the sum of the longest diameter of target lesions; progressive disease, 20% increase in the sum of the longest diameter of target lesions; stable disease, small changes that do not meet above criteria. Disease assessment was done at baseline and then every 8 weeks after starting treatment, until the participant discontinued treatment.</description>
          <population>Targeted Population: all randomized participants who received at least one dose of study drug and had either the histological subtypes of adenocarcinoma with bronchioloalveolar carcinoma features or pure bronchioloalveolar carcinoma, or were never smokers with any histology of non-small cell lung cancer (NSCLC)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tumor Response in the Non-Targeted Population Through the End of Treatment</title>
        <description>Baseline and then every 8 weeks through end of treatment (end of treatment for each participant was dependent on when the participant withdrew from study therapy due to disease progression, an adverse event or participant decision)</description>
        <time_frame>Baseline and then every 8 weeks through end of treatment</time_frame>
        <population>Non-Targeted Population: all randomized participants who received at least one dose of study drug but who did not meet the criteria for inclusion in the Targeted Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response in the Non-Targeted Population Through the End of Treatment</title>
          <description>Baseline and then every 8 weeks through end of treatment (end of treatment for each participant was dependent on when the participant withdrew from study therapy due to disease progression, an adverse event or participant decision)</description>
          <population>Non-Targeted Population: all randomized participants who received at least one dose of study drug but who did not meet the criteria for inclusion in the Targeted Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) at Four Months in the Targeted Population</title>
        <description>Percentage of participants in the Targeted Population, at 4 months after starting study drug, who were alive and without disease progression.</description>
        <time_frame>From randomization and then every 8 weeks up to four months</time_frame>
        <population>Targeted Population</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) at Four Months in the Targeted Population</title>
          <description>Percentage of participants in the Targeted Population, at 4 months after starting study drug, who were alive and without disease progression.</description>
          <population>Targeted Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Kaplan-Meier estimate</param_type>
            <param_value>34.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>55.4</ci_upper_limit>
            <estimate_desc>Percentage of surviving participants who were progression free 4 months after the date of randomization</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Kaplan-Meier estimate</param_type>
            <param_value>19.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>36.4</ci_upper_limit>
            <estimate_desc>Percentage of surviving participants who were progression free 4 months after the date of randomization</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) at Four Months in the Non-Targeted Population</title>
        <description>Percentage of participants in the Non-Targeted Population, at 4 months after starting study drug, who were alive and without disease progression.</description>
        <time_frame>From randomization and then every 8 weeks up to four months</time_frame>
        <population>Non-Targeted Population: all randomized participants who received at least one dose of study drug but who did not meet the criteria for inclusion in the Targeted Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) at Four Months in the Non-Targeted Population</title>
          <description>Percentage of participants in the Non-Targeted Population, at 4 months after starting study drug, who were alive and without disease progression.</description>
          <population>Non-Targeted Population: all randomized participants who received at least one dose of study drug but who did not meet the criteria for inclusion in the Targeted Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Kaplan-Meier estimate</param_type>
            <param_value>27.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.9</ci_lower_limit>
            <ci_upper_limit>42.3</ci_upper_limit>
            <estimate_desc>Percentage of surviving participants who were progression free 4 months after the date of randomization</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Kaplan-Meier estimate</param_type>
            <param_value>18.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.9</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
            <estimate_desc>Percentage of surviving participants who were progression free 4 months after the date of randomization</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Showed Certain Biomarkers in Their Serum or Tumor Tissue</title>
        <description>To further characterize the participant population, these biomarkers could be tested: serum levels of ErbB1 and ErbB2; intra-tumoral expression of ErbB1, ErbB2, etc.; mutations in ErbB1, ErbB2, and k-ras. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, serum biomarkers were not analyzed.</description>
        <time_frame>From randomization to disease progression (for serum biomarkers) or until analyses of tumor tissue samples</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Showed Certain Biomarkers in Their Serum or Tumor Tissue</title>
          <description>To further characterize the participant population, these biomarkers could be tested: serum levels of ErbB1 and ErbB2; intra-tumoral expression of ErbB1, ErbB2, etc.; mutations in ErbB1, ErbB2, and k-ras. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, serum biomarkers were not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of Lapatinib</title>
        <description>To characterize the PK (absorption, distribution, metabolism, and excretion) of the study drug lapatinib in the participant population. PK is defined as the concentration of drug in a participant’s blood at certain time points after the drug was taken by mouth. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, pharmacokinetics were not analyzed.</description>
        <time_frame>From randomization to time of PK period completed: Day 1 (first dose) and Days 2, 28, and 29 while participant was on study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Lapatinib</title>
          <description>To characterize the PK (absorption, distribution, metabolism, and excretion) of the study drug lapatinib in the participant population. PK is defined as the concentration of drug in a participant’s blood at certain time points after the drug was taken by mouth. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, pharmacokinetics were not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacogenetics (PgX)</title>
        <description>To (1) investigate the relationship between genetic variants in specific genes and the absorption, distribution, metabolism, and excretion (pharmacokinetics) of lapatinib, and to (2) investigate the relationship between genetic variants in select genes in DNA and the response (safety, efficacy, and tolerability) to lapatinib. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, pharmacogenetics were not analyzed.</description>
        <time_frame>From randomization at every 4-week assessment through end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacogenetics (PgX)</title>
          <description>To (1) investigate the relationship between genetic variants in specific genes and the absorption, distribution, metabolism, and excretion (pharmacokinetics) of lapatinib, and to (2) investigate the relationship between genetic variants in select genes in DNA and the response (safety, efficacy, and tolerability) to lapatinib. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, pharmacogenetics were not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Standard survey forms were completed by the participant at scheduled assessments to find out how the participant felt while on study. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, quality of life was not analyzed.</description>
        <time_frame>Baseline and then every 4 weeks through end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Standard survey forms were completed by the participant at scheduled assessments to find out how the participant felt while on study. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, quality of life was not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response</title>
        <description>Time from randomization until first documented evidence of partial or complete tumor response, measured using standard criteria (RECIST). Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, time to response was not analyzed.</description>
        <time_frame>From randomization and then every 8 weeks to time of response to study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response</title>
          <description>Time from randomization until first documented evidence of partial or complete tumor response, measured using standard criteria (RECIST). Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, time to response was not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>For those participants who show a complete or partial response, duration of response would be time from first documented evidence of response (complete or partial response by RECIST) until disease progression or death, if sooner. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, duration of response was not analyzed.</description>
        <time_frame>Time from first documented evidence of response to study treatment and then every 8 weeks until disease progression or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>For those participants who show a complete or partial response, duration of response would be time from first documented evidence of response (complete or partial response by RECIST) until disease progression or death, if sooner. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, duration of response was not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression</title>
        <description>Time from randomization until the first documented sign of disease progression or death due to any cause, if sooner. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, time to tumor progression was not analyzed.</description>
        <time_frame>From randomization and then every 8 weeks to disease progression or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression</title>
          <description>Time from randomization until the first documented sign of disease progression or death due to any cause, if sooner. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, time to tumor progression was not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is measured as the time from randomization until death due to any cause. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, overall survival was not analyzed.</description>
        <time_frame>From randomization and then every 8 weeks while on study drug and then every 3 months as follow-up until death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is measured as the time from randomization until death due to any cause. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, overall survival was not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Review of Non-small Cell Lung Cancer (NSCLC) Histology (Cell Type) Using an Independent Review</title>
        <description>Comparison of the specific cell type (histology) of non-small cell lung cancer from participant’s tissue samples, as determined by local pathologist, to the type determined by an independent pathologist. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, NSCLC histology was not analyzed.</description>
        <time_frame>Anytime from Baseline through end of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib 1500 mg QD</title>
            <description>Oral lapatinib 1500 mg once daily (QD)</description>
          </group>
          <group group_id="O2">
            <title>Lapatinib 500 mg BID</title>
            <description>Oral lapatinib 500 mg twice daily (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Review of Non-small Cell Lung Cancer (NSCLC) Histology (Cell Type) Using an Independent Review</title>
          <description>Comparison of the specific cell type (histology) of non-small cell lung cancer from participant’s tissue samples, as determined by local pathologist, to the type determined by an independent pathologist. Based on the interim analysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment into the study was stopped due to lack of efficacy on both treatment arms; therefore, NSCLC histology was not analyzed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lapatinib 1500 mg QD</title>
          <description>Oral lapatinib 1500 mg once daily (QD)</description>
        </group>
        <group group_id="E2">
          <title>Lapatinib 500 mg BID</title>
          <description>Oral lapatinib 500 mg twice daily (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhea hemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyangitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Based on interim analysis and predefined stopping rules for futility, the study was discontinued due to lack of efficacy. At that time, no additional participants were added; enrolled participants could continue on treatment, following the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

